Collegium Pharmaceutical, Inc. Lands $20,000,000 Series D Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6f5d478e-63ac-42c4-9e7b-a9c9ffaec05e&Preview=1 -
Date
7/15/2008 -
Company Name
Collegium Pharmaceutical, Inc. -
Mailing Address
400 Highland Corporate Drive Cumberland, RI 02864 -
Company Description
Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs. We apply customized pharmaceutical formulations and intellectual property (IP) strategies to drugs that are safe and effective, creating a portfolio of improved pharmaceutical products with a shorter time to market. -
Website
http://www.collegiumpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series D -
Proceeds Purposes
The proceeds from this financing will be used primarily to support the continued development of the Company’s lead DETERx™ product candidate, COL-003, a tamper resistant, abuse-deterrent, sustained release oxycodone formulation. -
M&A Terms
-
Venture Investor
Frazier Healthcare Ventures -
Venture Investor
Boston Millennia Partners
